Literature DB >> 16955692

An update on angiogenic gene therapy: vascular endothelial growth factor and other directions.

Seppo Ylä-Herttuala1.   

Abstract

Therapeutic angiogenesis is a promising new concept for the treatment of tissue ischemia and other related medical conditions or processes, such as wound healing. Members of the vascular endothelial growth factor (VEGF) family are among the most powerful modulators of vascular growth; they regulate vascular growth and maintenance during embryogenesis and in adults. Despite progress in basic research and preclinical animal studies of therapeutic angiogenesis, significant problems still exist in translating experimental findings into beneficial clinical approaches. This review summarizes these problems and highlights recent findings in the field of therapeutic angiogenesis using VEGF and other factors, with special reference to potential clinical applications. Also, in order to better optimize vectors, doses and treatment approaches, it is proposed that the analysis of new parameters is introduced. These parameters consist of: i) spreading throughout and reaching appropriate cells in the target tissue, ii) transfection efficiency, iii) expression strength, and iv) duration of expression. It is envisaged that this 'STED' analysis will aid the clinical development of gene therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16955692

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  8 in total

Review 1.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

2.  The Pharmacology of Gene Therapy.

Authors:  Seppo Ylä-Herttuala
Journal:  Mol Ther       Date:  2017-07-22       Impact factor: 11.454

3.  Cathepsin L derived from skeletal muscle cells transfected with bFGF promotes endothelial cell migration.

Authors:  Ji Hyung Chung; Eun Kyoung Im; Tae Won Jin; Seung-Min Lee; Soo Hyuk Kim; Eun Young Choi; Min-Jeong Shin; Kyung Hye Lee; Yangsoo Jang
Journal:  Exp Mol Med       Date:  2011-04-30       Impact factor: 8.718

Review 4.  Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.

Authors:  Larissa Lipskaia; Elie R Chemaly; Lahouaria Hadri; Anne-Marie Lompre; Roger J Hajjar
Journal:  Expert Opin Biol Ther       Date:  2010-01       Impact factor: 4.388

Review 5.  Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling.

Authors:  Jeff S Isenberg; William A Frazier; Murali C Krishna; David A Wink; David D Roberts
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

6.  Induction of aberrant vascular growth, but not of normal angiogenesis, by cell-based expression of different doses of human and mouse VEGF is species-dependent.

Authors:  Edin Mujagic; Roberto Gianni-Barrera; Marianna Trani; Abdulsamie Patel; Lorenz Gürke; Michael Heberer; Thomas Wolff; Andrea Banfi
Journal:  Hum Gene Ther Methods       Date:  2013-02       Impact factor: 2.396

7.  Therapeutic manipulation of angiogenesis with miR-27b.

Authors:  Dorina Veliceasa; Dauren Biyashev; Gangjian Qin; Sol Misener; Alexander Roy Mackie; Raj Kishore; Olga V Volpert
Journal:  Vasc Cell       Date:  2015-06-24

8.  FACS-purified myoblasts producing controlled VEGF levels induce safe and stable angiogenesis in chronic hind limb ischemia.

Authors:  Thomas Wolff; Edin Mujagic; Roberto Gianni-Barrera; Philipp Fueglistaler; Uta Helmrich; Heidi Misteli; Lorenz Gurke; Michael Heberer; Andrea Banfi
Journal:  J Cell Mol Med       Date:  2012-01       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.